Liver Disease and Liver Cancer

Sharon Hodgson Excerpts

Thursday 25th April 2024 Westminster Hall

[Mrs Sharon Hodgson (Washington and Sunderland West) (Lab)]

It is a pleasure to serve under your chairmanship today, Sir Christopher. I thank my hon. Friend the Member for Stockport (Navendu Mishra) and the hon. Member for Glasgow Central (Alison Thewliss) for securing this important debate, and hon. Members for their excellent opening speeches, setting the scene.

Addressing liver disease and cancer has for far too long been put on the back burner. Despite the vital work of organisations like the British Liver Trust and Liver Cancer UK, liver disease remains a leading cause of premature death, and is now the fastest rising cause of cancer death in the UK, yet 90% of liver disease is preventable, and it is in many cases reversible. It is a travesty, and an indictment of the state of our healthcare system, that three quarters of people living in the UK are diagnosed when it is too late for effective intervention or treatment.

I am acutely aware of the effect that liver disease has, because Washington and Sunderland West is at the heart of this public health crisis, which disproportionately affects those living in the north-east. In Sunderland, hospital admission rates due to liver disease were, shockingly, 84% higher than the national average in 2022-23, and the region suffers one of the worst hospital admission rates in England for women with liver disease. We see the hand of inequality stretch even further, as over a third of all premature deaths reported in 2022 were in the north of England, despite the Government’s manifesto pledge and levelling-up mission to narrow the gap in healthy life expectancy. The Government’s inaction on tackling health inequality is clearly indicated by the simple fact that, since the Marmot review was published in 2010, health inequalities have widened.

If we are to tackle this issue, we must finally start to tackle its root causes. We must reform our approach to liver disease and cancer, no longer allowing the prevailing myth of it being self-inflicted—as my hon. Friend the Member for Stockport said in his opening speech—to impact policy decisions, when we know the fatal consequences of the status quo. Despite hospital admissions caused by liver disease having risen by almost 80% over the last decade, liver disease was omitted from the major conditions strategy and was overlooked in the core modalities for community diagnostic centres.

We owe it to all those affected by liver disease to set out a proper plan to improve diagnosis and treatment. We must take a holistic approach, focusing on improving every area, from research to prevention to treatment. I believe the creation of the new nationally endorsed diagnostic pathway will be key to ensuring earlier diagnosis, with less regional disparity. In the short term, I urge Ministers to deliver a prompt and comprehensive review of adult liver services by NHS England, and to ensure that local health commissioners learn from areas where fully effective pathways for the early detection and management of liver disease are already in place.

We must no longer ignore the simple truth that we cannot improve outcomes for liver disease and cancer if the staffing crisis, long waiting times for diagnosis and barriers to accessing specialist care once diagnosed continue. We are seeing it with liver disease, where the cross-over of specialist services means that those affected experience the pressures on the NHS acutely, but the same story is told in every aspect of healthcare. We must deliver more scans and more appointments every year if we are to catch cancer early.

I am pleased that Labour has committed to a £171 million a year investment to provide the NHS with state-of-the-art equipment and new technology to cut waiting times and speed up diagnosis and treatment. I very much hope we can take momentum forward from this debate and push the Government to finally implement measures to increase diagnostic rates, invest in preventative measures and improve treatment for liver disease and cancer, because those seeking treatment cannot afford for us not to.